Cargando…
Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706367/ https://www.ncbi.nlm.nih.gov/pubmed/34941718 http://dx.doi.org/10.3390/toxins13120881 |
_version_ | 1784622175447154688 |
---|---|
author | Tambasco, Nicola Filidei, Marta Nigro, Pasquale Parnetti, Lucilla Simoni, Simone |
author_facet | Tambasco, Nicola Filidei, Marta Nigro, Pasquale Parnetti, Lucilla Simoni, Simone |
author_sort | Tambasco, Nicola |
collection | PubMed |
description | Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic condition, and spontaneous recovery is rare. Intramuscular injections of Botulinum Toxin (BoNT) are routinely used as HFS treatment. Methods: We reviewed published articles between 1991 and 2021 regarding the effectiveness and safety of BoNT in HFS as well as any reported differences among BoNT formulations. Results: The efficacy of BoNT for HFS treatment ranged from 73% to 98.4%. The mean duration of the effect was around 12 weeks. Effectiveness did not decrease over time. Adverse effects were usually mild and transient. The efficacy and tolerability of the different preparations appeared to be similar. Among the studies, dosage, injected muscles, intervals of treatment, and rating scales were variable, thus leading to challenges in comparing the results. Conclusions: BoNT was the treatment of choice for HFS due to its efficacy and safety profile. Further studies are needed to investigate the factors that influence the outcome, including the optimal timing of treatment, injection techniques, dosage, and the best selection criteria for formulations. |
format | Online Article Text |
id | pubmed-8706367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87063672021-12-25 Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies Tambasco, Nicola Filidei, Marta Nigro, Pasquale Parnetti, Lucilla Simoni, Simone Toxins (Basel) Review Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic condition, and spontaneous recovery is rare. Intramuscular injections of Botulinum Toxin (BoNT) are routinely used as HFS treatment. Methods: We reviewed published articles between 1991 and 2021 regarding the effectiveness and safety of BoNT in HFS as well as any reported differences among BoNT formulations. Results: The efficacy of BoNT for HFS treatment ranged from 73% to 98.4%. The mean duration of the effect was around 12 weeks. Effectiveness did not decrease over time. Adverse effects were usually mild and transient. The efficacy and tolerability of the different preparations appeared to be similar. Among the studies, dosage, injected muscles, intervals of treatment, and rating scales were variable, thus leading to challenges in comparing the results. Conclusions: BoNT was the treatment of choice for HFS due to its efficacy and safety profile. Further studies are needed to investigate the factors that influence the outcome, including the optimal timing of treatment, injection techniques, dosage, and the best selection criteria for formulations. MDPI 2021-12-09 /pmc/articles/PMC8706367/ /pubmed/34941718 http://dx.doi.org/10.3390/toxins13120881 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tambasco, Nicola Filidei, Marta Nigro, Pasquale Parnetti, Lucilla Simoni, Simone Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies |
title | Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies |
title_full | Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies |
title_fullStr | Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies |
title_full_unstemmed | Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies |
title_short | Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies |
title_sort | botulinum toxin for the treatment of hemifacial spasm: an update on clinical studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706367/ https://www.ncbi.nlm.nih.gov/pubmed/34941718 http://dx.doi.org/10.3390/toxins13120881 |
work_keys_str_mv | AT tambasconicola botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies AT filideimarta botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies AT nigropasquale botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies AT parnettilucilla botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies AT simonisimone botulinumtoxinforthetreatmentofhemifacialspasmanupdateonclinicalstudies |